Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life.

Iododoxorubicin 80 mg m-2 i.v. was given 3 weekly for a maximum of six cycles as first-line chemotherapy to 14 evaluable women with metastatic breast cancer. The response rate was 14% (95% confidence intervals 4-40%); median time to progression was 3.5 months (range 0.7 to > 9.3) and median survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Twelves, C. J., Dobbs, N. A., Lawrence, M. A., Ramirez, A. J., Summerhayes, M., Richards, M. A., Towlson, K. E., Rubens, R. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968796/
https://www.ncbi.nlm.nih.gov/pubmed/8142261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968796/
https://www.ncbi.nlm.nih.gov/pubmed/8142261

Ejemplares similares